Literature DB >> 21822360

N-6 Substituted Deoxygenated Derivatives of L-like 5'-Noraristeromycin.

Henry Yu1, Tesfaye Serbessa.   

Abstract

Several N-6 substituted derivatives (4-11) of (+)-4'-deoxy-5'-noraristeromycin (2) and its unsaturated counterpart (3) have been prepared. The derivatives are designed to systematically vary the hydrophobic/hydrophilic balance of the lead compounds. These compounds were evaluated against a large number of viruses but, no significant antiviral activity was observed. Also, no cytotoxicity to host cells was found.

Entities:  

Year:  2010        PMID： 21822360      PMCID： PMC3149869          DOI： 10.4314/bcse.v24i3.60692

Source DB:  PubMed          Journal:  Bull Chem Soc Ethiop        ISSN： 1011-3924            Impact factor:   1.330


  13 in total

Review 1.  S-adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy.

Authors:  M S Wolfe; R T Borchardt
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

3.  Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-noraristeromycin derivatives with variations in the cyclopentyl ring substituents.

Authors:  K L Seley; S W Schneller; D Rattendi; S Lane; C J Bacchi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

Authors:  R A de Man; L M Wolters; F Nevens; D Chua; M Sherman; C L Lai; A Gadano; Y Lee; F Mazzotta; N Thomas; D DeHertogh
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

6.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

7.  The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

Authors:  S G Deeks; A Collier; J Lalezari; A Pavia; D Rodrigue; W L Drew; J Toole; H S Jaffe; A S Mulato; P D Lamy; W Li; J M Cherrington; N Hellmann; J Kahn
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

Review 8.  Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads.

Authors:  Stewart W Schneller
Journal:  Curr Top Med Chem       Date:  2002-10       Impact factor: 3.295

9.  Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells.

Authors:  R T Borchardt; B T Keller; U Patel-Thombre
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

Review 10.  Hepatitis B and C virus infections in the immune compromised.

Authors:  Geoffrey H Haydon; David J Mutimer
Journal:  Curr Opin Infect Dis       Date:  2003-10       Impact factor: 4.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.